UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
25 February 2026 - “Haleon Preliminary 2025 Full Year
Results”
|
|
25 February 2026 - “Haleon
Preliminary 2025 Full Year Results”
|
99.1
Haleon plc: Preliminary 2025 Full Year Results
25 February 2026: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces its
preliminary full year results statement for the year ended 31
December 2025 is available at http://www.rns-pdf.londonstockexchange.com/rns/2433U_1-2026-2-24.pdf.
The preliminary full year results statement will also be available
on the Haleon website www.haleon.com/investors,
and the results have been submitted in full unedited text to the
Financial Conduct Authority's National Storage Mechanism and will
shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Dividend
Reflecting the strength of FCF generation during the year,
alongside strong organic operating profit growth, the Board is
proposing a 2025 total dividend of 7.1p per ordinary share which
represents a payout ratio of approximately 38% of 2025 adjusted
earnings (2024: 37%). This includes a final dividend of 4.9p per
ordinary share.
Subject to shareholder approval, the final dividend will be paid on
14 May 2026 to holders of ordinary shares and US American
Depositary Shares (ADS) on the register as of 10 April 2026 (the
record date). The ex-dividend date for ordinary shares will be 9
April 2026 and for US American Depositary Shares (ADS) 10 April
2026. For ordinary shareholders wishing to participate in the
Dividend Reinvestment Programme (DRIP), the election deadline will
be 24 April 2026. The DRIP is provided by Equiniti Financial
Services Limited, more information is available
at www.shareview.co.uk/info/drip.
Subject to market conditions and Board approval, Haleon expects to
grow its ordinary dividend at least in line with adjusted
earnings.
Presentation for analysts and shareholders
A recorded results presentation by Brian McNamara, Chief Executive
Officer, and Dawn Allen, Chief Financial Officer, will be available
shortly after 7:00am GMT (8:00 am CET) on 25 February 2026 and can
be accessed at www.haleon.com/investors.
This will be followed by a Q&A session at 8:45am GMT (9:45am
CET).
For analysts and shareholders wishing to ask questions, please use
the dial-in details below which will have a Q&A
facility:
|
UK:
|
+44 (0) 808 189 0158
|
|
US:
|
+1 855 979 6654
|
|
All other:
|
+44 (0) 203 936 2999
|
|
Passcode:
|
049869
|
An archived webcast of the Q&A call will be available later on
the day of the results and can be accessed
at www.haleon.com/investors.
This information contains regulated information as per 6.3.7R of
the Disclosure and Transparency Rules of the Financial Conduct
Authority.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
||
|
Jo
Russell
|
+44
7787 392441
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Victoria
Durman
|
+44 7894 505730
|
|
Email: [email protected]
|
Email: [email protected]
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are built on
trusted science, innovation and deep human
understanding.
For more information please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
February 25, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|